Thus, both CD176-CARs were shown to mediate specific T-cell activation and IFN-γ release in a comparable extent upon recognition of CD176 on cancer cell lines as models for lung and pancreatic tumors and leukemia. This evidence concerns the gene IFNG and pancreatic neoplasm.